Researchers Identify Specific Potential Therapeutic Targets For Aggressive Form Of Pancreatic Cancer | Latest News RSS Feed

Researchers Identify Specific Potential Therapeutic Targets For Aggressive Form Of Pancreatic Cancer - Latest News


Treatment Options for Advanced Pancreatic Cancer

A Grothey received research support from Genentech ... is an alternative first-line therapeutic option for patients with metastatic pancreatic cancer, but does have increased toxicity. read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

Chemical changes to peptide siRNA-carrier enhance gene silencing for future cancer drugs

Cancer therapies face multiple challenges, including off-target side effects and low efficacy. RNAi-based therapeutics have great potential to overcome these specific treatment challenges. read more

Nearly S$10 million awarded to research on deadly brain cancer

Glioblastoma (GBM) is a highly aggressive type of brain cancer ... information to identify and prioritise potential drugs that might be effective on therapeutic targets within the STAT3 pathway. read more

Looking for other news?


Intralesional Therapies Help Bridge the Gap Between Improved Results and Less Toxicity

Researchers are investigating other potential targets ... therapy. Down the line, combination treatment with intralesional therapy and checkpoint inhibitors may even play a role in the treatment of ... read more

Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

In the past, this process to identify alternatively spliced forms ... target: An IsoMSLN monoclonal antibody specific binder for indication-specific solid malignancies such as ovarian cancer ... read more

Division of Molecular Pathology

Researchers are also examining changes in the cancer epigenome to provide understanding of tumour development and response to treatment; and using deep sequencing technologies to identify specific ... read more

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable ... read more

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma

Novocure announced a clinical trial collaboration with GT Medical Technologies to evaluate TTFields together with GammaTile® Therapy in recurrent GBM. read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us